Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn
William N
WN
Metabolic Diseases Chemistry, Research and Development, Bristol-Myers Squibb Co, Princeton, New Jersey 08543, USA.
D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005947:Glucose / Q000378:metabolism*; D005960:Glucosides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D005947:Glucose